Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012

FDG-PET safe and accurate in detecting dementia, Alzheimer's

In a new review of imaging studies spanning more than ten years, scientists find that a method of positron emission tomography (PET) safely and accurately detects dementia, including the most common and devastating form among the elderly, Alzheimer's disease.

7 Jan 2012

Scripps professor receives pair of notable grants to study kinesin

Sathyanaryanan Puthanveettil, an assistant professor on the Florida campus of The Scripps Research Institute, has been awarded a pair of notable grants to study a critical component of long-term memory formation.

6 Jan 2012

AstraZeneca plans to progress Targacept's AZD1446 as treatment for AD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept's product candidate AZD1446 as a treatment for Alzheimer's disease.

5 Jan 2012

Doctors may need to adjust seizure drug doses for people with HIV/AIDS: New AAN guideline

A new guideline issued by the American Academy of Neurology recommends doctors use caution when choosing seizure drugs for people with HIV/AIDS to avoid potential drug interactions.

5 Jan 2012

Probiodrug secures EUR 15M for clinical development of PQ912

Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.

5 Jan 2012

Working Group recommends use of biomarkers in AD clinical trials

A group of thought leaders in Alzheimer's disease says the science is solid and the time has come for more widespread use of biomarkers in Alzheimer disease (AD) clinical trials, to speed the identification of effective disease-modifying treatments for this incurable disorder.

5 Jan 2012

UCSD scientist honored for Down syndrome research

William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine and Chairman of the U.S. Scientific Advisory Committee of the J-r-me Lejeune Foundation, was recognized by U.S. Congressman Pete Sessions from the floor of the House of Representatives in December. Sessions said of Mobley - who received the International Sisley-J-r-me Lejeune Prize in a ceremony at the Museum of Medical History in Paris on December 8.

5 Jan 2012

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

Ironwood Pharmaceuticals, Inc. and Bionomics Limited today announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

5 Jan 2012

NGP receives investment from Abbott to develop NGP 555 for AD

NeuroGenetic Pharmaceuticals, Inc. (NGP), a privately held biopharmaceutical company focused on Alzheimer's disease (AD) therapeutics, has received an investment from Abbott Biotech Ventures.

5 Jan 2012

Amyloid precursor protein fragment may be a biomarker for autism

Immune system abnormalities that mimic those seen with autism spectrum disorders have been linked to the amyloid precursor protein (APP), reports a research team from the University of South Florida's Department of Psychiatry and the Silver Child Development Center.

4 Jan 2012

Genomic architecture predisposes supercentenarians to age-related diseases

The first-ever published whole-genome sequences of not just one, but two supercentenarians, aged more than 114 years, reveal that both unusual and common genetic phenomena contribute to the genetic background of extreme human longevity.

4 Jan 2012

Bingo enhances cognitive performance in people with Alzheimer's and Parkinson's disease

Bingo, a popular activity in nursing homes, senior centers and assisted-living facilities, has benefits that extend well beyond socializing. Researchers found high-contrast, large bingo cards boost thinking and playing skills for people with cognitive difficulties and visual perception problems produced by Alzheimer's disease (AD) and Parkinson's disease (PD).

4 Jan 2012

Low T Center for testosterone replacement therapy opens new clinic in Denver

Low T Center is opening a new clinic at 12213 North Pecos, Westminster, Co., a suburb of Denver on Tuesday, January 3, 2012. This men's oriented clinic will provide testosterone replacement therapy in the form of testosterone injections for men around the ages of 40-60 years old.

4 Jan 2012

Origin of osteoporosis could be directly linked to manganese depletion

The loss of manganese could mean that calcium does not stick to bones and could cause osteoporosis. This is the new theory put forward by researchers at the University of Castilla-La Mancha (UCLM) in Spain after studying deer antlers.

3 Jan 2012

Vitamins and omega 3 fatty acids in blood could stave off dementia: Study

A new study has shown that higher blood levels of omega-3 fatty acids, vitamin B, vitamin C, vitamin D and vitamin E are associated with better mental functioning in the elderly.

3 Jan 2012

Hormone Adiponectin linked to dementia in women: Study

New research has shown that there may be a possible connection between a hormone found in body fat and the risk of dementia, adding to the growing evidence on the potential link between the condition and diabetes.

3 Jan 2012

Combination of biomarkers indicates high risk of Alzheimer's in the future

Physician Oskar Hansson and his research group are studying biomarkers - substances present in spinal fluid and linked to Alzheimer's disease. The group has studied close to 140 people with mild memory impairment, showing that a certain combination of markers (low levels of the substance beta-amyloid and high levels of the substance tau) indicate a high risk of developing Alzheimer's disease in the future.

3 Jan 2012

Adiponectin may play a role in development of all-cause dementia and AD in women

A hormone derived from visceral fat called adiponectin may play a role as a risk factor for development of all-cause dementia and Alzheimer disease (AD) in women, according to a study published Online First by the Archives of Neurology, one of the JAMA/Archives journals.

3 Jan 2012

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

Cerebrospinal fluid levels of Aβ42 appear to be decreased at least five to 10 years before some patients with mild cognitive impairment develop Alzheimer disease (AD) dementia whereas other spinal fluid levels seem to be later markers of disease, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Jan 2012

Alzheimer's Disease News and Research

Further Reading

Studies identify genes and small molecules against protein conformational diseases

FDG-PET safe and accurate in detecting dementia, Alzheimer's

Scripps professor receives pair of notable grants to study kinesin

AstraZeneca plans to progress Targacept's AZD1446 as treatment for AD

Doctors may need to adjust seizure drug doses for people with HIV/AIDS: New AAN guideline

Probiodrug secures EUR 15M for clinical development of PQ912

Working Group recommends use of biomarkers in AD clinical trials

UCSD scientist honored for Down syndrome research

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

NGP receives investment from Abbott to develop NGP 555 for AD

Amyloid precursor protein fragment may be a biomarker for autism

Genomic architecture predisposes supercentenarians to age-related diseases

Bingo enhances cognitive performance in people with Alzheimer's and Parkinson's disease

Low T Center for testosterone replacement therapy opens new clinic in Denver

Origin of osteoporosis could be directly linked to manganese depletion

Vitamins and omega 3 fatty acids in blood could stave off dementia: Study

Hormone Adiponectin linked to dementia in women: Study

Combination of biomarkers indicates high risk of Alzheimer's in the future

Adiponectin may play a role in development of all-cause dementia and AD in women

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News